Liminatus Pharma, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| DEShaw | quant | 83.4K | $3.33K | 0.00% | Unchanged | 2026-03-31 |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| LIMN | -20.00% | -28.70% | -73.11% | -96.98% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -22.97% | -24.06% | -69.67% | -109.67% |